Glen J. Weiss - Concepedia

Author

Glen J. Weiss

Translational Genomics Research Institute ORCID

Also Known As

G Hostetter, G J Weiss, G WEISS, G Weiss, G. J. Weiss, G. Weiss, G.J. Weiss, GLEN WEISS, Glen J Weiss, Glen J. Weiss

381

Publications

12.7K

Citations

H-Index

108

Concepts

All Affiliations

Translational Genomics Research Institute Goodyear (United States)Western Regional Medical Center Sarah Cannon Cancer Treatment Centers of America

About

Glen J. Weiss is an author at Translational Genomics Research Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	63	4.5K
2	Health Sciences	9	9	413
3	Allergy	2	2	68
4	Biology	2	2	54
5	Engineering	1	1	72

Glen J. Weiss

123

Publications

10.9K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin, New England Journal of Medicine	2009	1.1K
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Cancer Discovery	2013	691
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor William D. Tap, Zev A. Wainberg, Stephen P. Anthony, New England Journal of Medicine	2015	571
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors Patricia LoRusso, Charles M. Rudin, Josina C. Reddy, Clinical Cancer Research	2011	544
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial Scott Gettinger, Lyudmila Bazhenova, Corey J. Langer, The Lancet Oncology Other MalignanciesMedicinePharmacologyPathologyBronchial Neoplasm	2016	348
miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer Kristen M. Foss, Chao Sima, Donatella Ugolini, Journal of Thoracic Oncology Prognostic BiomarkersSerum-based Microrna BiomarkersMedicineBiomarker TargetPathology	2011	286
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Clinical Cancer Research	2016	262
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Glen J. Weiss, Lynne Bemis, Eri Nakajima, Annals of Oncology Egfr ExpressionOncologyMedicinePathologyCancer Genomics	2008	240
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart, Investigational New Drugs OncologyPolymer-drug ConjugateMedicineFirst-in-human Phase 1/2ATumor Targeting	2013	219

Page 1